Stockscreener 앱 받기
127.41
0.09%
-0.12
시간 외 거래:
131.00
3.59
+2.82%
전일 마감가:
$127.53
열려 있는:
$128.64
하루 거래량:
1.04M
Relative Volume:
1.13
시가총액:
$7.48B
수익:
$551.35M
순이익/손실:
$-189.33M
주가수익비율:
-38.71
EPS:
-3.2916
순현금흐름:
$-35.09M
1주 성능:
+4.02%
1개월 성능:
-11.53%
6개월 성능:
+13.33%
1년 성능:
+27.65%
1일 변동 폭
$126.67
$131.78
1주일 범위
$122.69
$132.24
52주 변동 폭
$73.16
$148.11
Glaukos Corp Stock (GKOS) Company Profile
명칭
Glaukos Corp
전화
949-367-9600
주소
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corp
|
127.41 | 7.64B | 551.35M | -189.33M | -35.09M | -3.2916 |
ABT
Abbott Laboratories
|
88.50 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.14 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.14 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.95 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.68 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Glaukos Corp Stock (GKOS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-27 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | 개시 | Goldman | Buy |
| 2025-05-01 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-12-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-12-06 | 개시 | UBS | Buy |
| 2024-12-02 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-12-21 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-04 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-11-28 | 개시 | Truist | Buy |
| 2023-11-08 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | 개시 | Mizuho | Neutral |
| 2022-12-19 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-12-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-10-14 | 재개 | Stephens | Overweight |
| 2022-10-04 | 개시 | Needham | Buy |
| 2022-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2022-02-03 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2021-11-03 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-07-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-01-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | 업그레이드 | Citigroup | Sell → Neutral |
| 2020-12-09 | 개시 | Oppenheimer | Perform |
| 2020-11-17 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-06-15 | 개시 | Jefferies | Hold |
| 2020-03-05 | 개시 | Citigroup | Sell |
| 2020-02-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-01-06 | 업그레이드 | Berenberg | Hold → Buy |
| 2019-12-12 | 다운그레이드 | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | 개시 | BTIG Research | Neutral |
| 2018-08-30 | 개시 | Berenberg | Hold |
| 2018-08-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-08-03 | 재확인 | Stifel | Hold |
| 2018-06-21 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-04-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-01 | 재확인 | Cantor Fitzgerald | Buy |
| 2017-03-02 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-01-06 | 업그레이드 | Stifel | Hold → Buy |
| 2016-10-27 | 개시 | Wells Fargo | Outperform |
모두보기
Glaukos Corp 주식(GKOS)의 최신 뉴스
GKOS Maintained by Citigroup -- Price Target Raised to $162 - GuruFocus
Clearbridge Investments LLC Lowers Stake in Glaukos Corporation $GKOS - MarketBeat
GKOS Reiterated by BTIG -- Price Target Maintained at $162 - GuruFocus
Stifel reiterates Glaukos stock rating on regulatory optimism By Investing.com - Investing.com South Africa
Stifel reiterates Glaukos stock rating on regulatory optimism - Investing.com
Glaukos Corp stock (US3773221029): analyst reiteration and adoption hopes keep momentum in focus - AD HOC NEWS
Why Is NYSE Composite Watching Glaukos’ iDose TR Adoption Momentum? - Kalkine Media
Midday Stock Roundup: Alignment Healthcare Surges - Orange County Business Journal
A Look At Glaukos (GKOS) Valuation After Recent Share Price Swings - Yahoo Finance
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pfizer (PFE), Dexcom (DXCM) and Glaukos (GKOS) - The Globe and Mail
Glaukos Corp Balance Sheet – XETR:6GJ - TradingView
Glaukos Corp Statistics – XETR:6GJ - TradingView
Glaukos Corp Cash Flow – XETR:6GJ - TradingView
Glaukos Corp Revenue Breakdown – XETR:6GJ - TradingView
Glaukos Corp stock (US3773221029): shares near recent highs as valuation comes into focus - AD HOC NEWS
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now - Yahoo Finance
Glaukos (NYSE: GKOS) investors approve board slate, pay and Ernst & Young - Stock Titan
Glaukos Corp. Hits Day High with Strong 7.43% Intraday Surge - Markets Mojo
Glaukos (GKOS) director Leana Wen granted RSUs and options in 2026 - Stock Titan
Glaukos (NYSE: GKOS) director granted new RSUs and stock options - Stock Titan
Glaukos (GKOS) director Denice Torres granted RSUs and stock options - Stock Titan
Glaukos (GKOS) director Mark Foley receives new RSUs and stock options - Stock Titan
GLAUKOS (GKOS) director David Hoffmeister receives new RSU and option grants - Stock Titan
Glaukos Corp (GKOS) director Kliman receives new RSU and option awards - Stock Titan
Director at Glaukos (NYSE: GKOS) granted new stock units and options - Stock Titan
EBITDA per share of Glaukos Corp – FWB:6GJ - TradingView
Glaukos Corp stock (US3773221029): shares active on NYSE as market watches next catalysts - AD HOC NEWS
Glaukos (GKOS) director exercises 15,000 options at $24.69 - Stock Titan
Goldman Sachs Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $153 - Moomoo
Glaukos Corp. Stock Hits Day Low of $118.64 Amid Price Pressure - Markets Mojo
Glaukos (GKOS) Faces Selling Pressure Amid iDose Procedure Conce - GuruFocus
Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure - Quiver Quantitative
Nvidia To Rally More Than 123%? Here Are 10 Top Analyst Forecasts For Thursday - Sahm
GKOS Maintained by BTIG -- Price Target Raised to $162 - GuruFocus
Glaukos wins permanent J-code for Epioxa keratoconus therapy - MSN
BTIG raises Glaukos stock price target to $162 on product pipeline - Investing.com
Glaukos director Kliman sells $703,800 in stock By Investing.com - Investing.com Nigeria
Glaukos Corp stock (US3773221029): 52-week high and fresh insider sale stir investor interest - AD HOC NEWS
Glaukos director Kliman sells $703,800 in stock - Investing.com
Director at Glaukos (NYSE: GKOS) exercises options and sells 5,000 shares - Stock Titan
Glaukos stock hits 52-week high at $146.90 By Investing.com - Investing.com Nigeria
Glaukos stock hits 52-week high at $146.90 - Investing.com UK
Glaukos (GKOS) price target increased by 12.59% to 154.96 - MSN
DNB Asset Management AS Grows Stock Position in Glaukos Corporation $GKOS - MarketBeat
Glaukos Corp (GKOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Glaukos Corp 주식 (GKOS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hoffmeister David F | Director |
May 26 '26 |
Option Exercise |
24.69 |
15,000 |
370,350 |
47,671 |
| Kliman Gilbert H | Director |
May 14 '26 |
Option Exercise |
24.69 |
5,000 |
123,450 |
40,528 |
| Kliman Gilbert H | Director |
May 14 '26 |
Sale |
140.76 |
5,000 |
703,800 |
35,528 |
2.43%
자본화:
|
볼륨(24시간):